227 related articles for article (PubMed ID: 30685352)
21. Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity.
Ge Q; Maury E; Rycken L; Gérard J; Noël L; Detry R; Navez B; Brichard SM
Int J Obes (Lond); 2013 Jun; 37(6):874-80. PubMed ID: 22868830
[TBL] [Abstract][Full Text] [Related]
22. Blockade of Cannabinoid CB1 receptor attenuates the acquisition of morphine-induced conditioned place preference along with a downregulation of ERK, CREB phosphorylation, and BDNF expression in the nucleus accumbens and hippocampus.
Zhang J; Wang N; Chen B; Wang Y; He J; Cai X; Zhang H; Wei S; Li S
Neurosci Lett; 2016 Sep; 630():70-76. PubMed ID: 27461790
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoid 1 receptor blockade in the dorsal hippocampus prevents the reinstatement but not acquisition of morphine-induced conditioned place preference in rats.
Zhao X; Yao L; Wang F; Zhang H; Wu L
Neuroreport; 2017 Jul; 28(10):565-570. PubMed ID: 28492416
[TBL] [Abstract][Full Text] [Related]
24. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
26. Lithium Restores Age-related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome.
Guidi S; Bianchi P; Stagni F; Giacomini A; Emili M; Trazzi S; Ciani E; Bartesaghi R
CNS Neurol Disord Drug Targets; 2017; 16(7):812-819. PubMed ID: 27488422
[TBL] [Abstract][Full Text] [Related]
27. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.
Kleschevnikov AM; Belichenko PV; Faizi M; Jacobs LF; Htun K; Shamloo M; Mobley WC
J Neurosci; 2012 Jul; 32(27):9217-27. PubMed ID: 22764230
[TBL] [Abstract][Full Text] [Related]
28. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
[TBL] [Abstract][Full Text] [Related]
29. Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Stagni F; Raspanti A; Giacomini A; Guidi S; Emili M; Ciani E; Giuliani A; Bighinati A; Calzà L; Magistretti J; Bartesaghi R
Neurobiol Dis; 2017 Jul; 103():11-23. PubMed ID: 28359846
[TBL] [Abstract][Full Text] [Related]
30. Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome.
Stagni F; Salvalai ME; Giacomini A; Emili M; Uguagliati B; Xia E; Grilli M; Bartesaghi R; Guidi S
Neurobiol Dis; 2019 Sep; 129():44-55. PubMed ID: 31085229
[TBL] [Abstract][Full Text] [Related]
31. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R
Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome.
Giacomini A; Stagni F; Trazzi S; Guidi S; Emili M; Brigham E; Ciani E; Bartesaghi R
Neurobiol Dis; 2015 Oct; 82():385-396. PubMed ID: 26254735
[TBL] [Abstract][Full Text] [Related]
33. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.
Campos AC; Ortega Z; Palazuelos J; Fogaça MV; Aguiar DC; Díaz-Alonso J; Ortega-Gutiérrez S; Vázquez-Villa H; Moreira FA; Guzmán M; Galve-Roperh I; Guimarães FS
Int J Neuropsychopharmacol; 2013 Jul; 16(6):1407-19. PubMed ID: 23298518
[TBL] [Abstract][Full Text] [Related]
34. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.
Hawley LE; Prochaska F; Stringer M; Goodlett CR; Roper RJ
Pharmacol Biochem Behav; 2022 Jun; 217():173404. PubMed ID: 35576991
[TBL] [Abstract][Full Text] [Related]
35. Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome.
Dang V; Medina B; Das D; Moghadam S; Martin KJ; Lin B; Naik P; Patel D; Nosheny R; Wesson Ashford J; Salehi A
Biol Psychiatry; 2014 Feb; 75(3):179-88. PubMed ID: 23827853
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotective effect of cannabinoid receptor 1 antagonist in the MNU-induced retinal degeneration model.
Chen Y; Luo X; Liu S; Shen Y
Exp Eye Res; 2018 Feb; 167():145-151. PubMed ID: 29126840
[TBL] [Abstract][Full Text] [Related]
37. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
Tam J; Vemuri VK; Liu J; Bátkai S; Mukhopadhyay B; Godlewski G; Osei-Hyiaman D; Ohnuma S; Ambudkar SV; Pickel J; Makriyannis A; Kunos G
J Clin Invest; 2010 Aug; 120(8):2953-66. PubMed ID: 20664173
[TBL] [Abstract][Full Text] [Related]
38. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer.
Faizi M; Bader PL; Tun C; Encarnacion A; Kleschevnikov A; Belichenko P; Saw N; Priestley M; Tsien RW; Mobley WC; Shamloo M
Neurobiol Dis; 2011 Aug; 43(2):397-413. PubMed ID: 21527343
[TBL] [Abstract][Full Text] [Related]
40. Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome.
Roncacé V; Burattini C; Stagni F; Guidi S; Giacomini A; Emili M; Aicardi G; Bartesaghi R
Neurobiol Dis; 2017 Oct; 106():89-100. PubMed ID: 28651891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
